Literature DB >> 28109017

Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation.

Da Zhou1, Qin Pan1, Xiao-Lin Liu1, Rui-Xu Yang1, Yuan-Wen Chen1, Chang Liu2, Jian-Gao Fan1.   

Abstract

BACKGROUND AND AIM: Enterohepatic immunologic derangement is associated with non-alcoholic steatohepatitis. Here, we investigated whether Clostridium butyricum B1 (CB) would be an effective immune-targeted substance to attenuate steatohepatitis in mice.
METHODS: Thirty mice were randomized into a control group fed with common forage, a high-fat diet (HFD) group fed an HFD for 16 weeks, and an HFD + CB group treated with CB for the latter 8 weeks. Inflammation-associated or metabolism-associated genes in the liver or epididymal fat tissue were quantified; intrahepatic and intestinal immune factors were detected. Further short-chain fatty acids in the cecal contents or liver were measured, and differentiations of T cells in vitro were analyzed.
RESULTS: Characteristics of non-alcoholic steatohepatitis in the HFD group were obvious and were significantly attenuated in the HFD + CB group. The messenger RNA levels of monocyte chemotactic protein-1 and tumor necrosis factor-α in the liver and epididymal fat tissue were increased in the HFD group compared with the control group and were downregulated in the HFD + CB group. Intrahepatic and intestinal interferon-γ and interleukin (IL)-17 were significantly increased, whereas forkhead box P3, IL-4, and IL-22 were significantly decreased in the HFD group compared with the control group. However, these intrahepatic or intestinal immune changes were reversed after CB intervention. Furthermore, butyrate in the cecal content and liver of the HFD + CB group was significantly elevated. An in vitro investigation showed that sodium butyrate promoted CD4+ T cell differentiation into Th2, Th22, or Treg, whereas it inhibited CD4+ T cell differentiation into Th1 or Th17 under a cytokine milieu, which was mimicked by Trichostatin A.
CONCLUSION: Clostridium butyricum B1 could attenuate HFD-induced steatohepatitis in mice partially through butyrate-induced enterohepatic immunoregulation.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  Clostridium butyricum B1; NASH; butyrate; histone deacetylase inhibition; immunity

Mesh:

Substances:

Year:  2017        PMID: 28109017     DOI: 10.1111/jgh.13742

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  13 in total

Review 1.  Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes.

Authors:  Thomas Clavel; João Carlos Gomes-Neto; Ilias Lagkouvardos; Amanda E Ramer-Tait
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

Review 2.  Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.

Authors:  Hamed Ebrahimzadeh Leylabadlo; Reza Ghotaslou; Hossein Samadi Kafil; Mohammad Mehdi Feizabadi; Seyed Yaghoub Moaddab; Safar Farajnia; Elham Sheykhsaran; Sarvin Sanaie; Dariush Shanehbandi; Hossein Bannazadeh Baghi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-12-11       Impact factor: 3.267

3.  Clinical Significance of Probiotics for Children with Idiopathic Nephrotic Syndrome.

Authors:  Tadashi Yamaguchi; Shoji Tsuji; Shohei Akagawa; Yuko Akagawa; Jiro Kino; Sohsaku Yamanouchi; Takahisa Kimata; Masaki Hashiyada; Atsushi Akane; Kazunari Kaneko
Journal:  Nutrients       Date:  2021-01-26       Impact factor: 5.717

4.  Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.

Authors:  Da Zhou; Yuan-Wen Chen; Ze-Hua Zhao; Rui-Xu Yang; Feng-Zhi Xin; Xiao-Lin Liu; Qin Pan; Huiping Zhou; Jian-Gao Fan
Journal:  Exp Mol Med       Date:  2018-12-03       Impact factor: 8.718

Review 5.  T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease.

Authors:  Javier Campos-Acuña; Daniela Elgueta; Rodrigo Pacheco
Journal:  Front Immunol       Date:  2019-02-15       Impact factor: 7.561

Review 6.  Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.

Authors:  Yi-Hsun Chen; Wei-Kai Wu; Ming-Shiang Wu
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

7.  zzm321990 Bifidobacterium breve CNCM I-4035, Lactobacillus paracasei CNCM I-4034 and Lactobacillus rhamnosus CNCM I-4036 Modulate Macrophage Gene Expression and Ameliorate Damage Markers in the Liver of Zucker-Leprzzm321990 fa/fazzm321990 Rats.

Authors:  Luis Fontana; Julio Plaza-Díaz; Paula Robles-Bolívar; Héctor Valente-Godínez; María José Sáez-Lara; Francisco Abadía-Molina; Carolina Gómez-Llorented; Ángel Gil; Ana I Álvarez-Mercado
Journal:  Nutrients       Date:  2021-01-11       Impact factor: 5.717

8.  Effect of Butyric Acid in the Proliferation and Migration of Junctional Epithelium in the Progression of Periodontitis: An In Vitro Study.

Authors:  Taichi Ishikawa; Daisuke Sasaki; Ryo Aizawa; Yu Shimoyama; Matsuo Yamamoto; Tarou Irié; Minoru Sasaki
Journal:  Dent J (Basel)       Date:  2021-04-16

Review 9.  Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?

Authors:  Nithin K K; Prakash Patil; Satheesh Kumar Bhandary; Vikram Haridas; Suchetha Kumari N; Sarathkumar E; Praveenkumar Shetty
Journal:  F1000Res       Date:  2021-04-06

10.  Clostridium Butyricum ZJU-F1 Benefits the Intestinal Barrier Function and Immune Response Associated with Its Modulation of Gut Microbiota in Weaned Piglets.

Authors:  Jie Fu; Tenghao Wang; Xiao Xiao; Yuanzhi Cheng; Fengqin Wang; Mingliang Jin; Yizhen Wang; Xin Zong
Journal:  Cells       Date:  2021-03-02       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.